A period without further weight loss does not automatically mean semaglutide has stopped helping or that tirzepatide is the next step. Weight-management treatment is reviewed for benefit, tolerability and the person's broader health, not one scale reading.[1]
Establish what has actually changed
A review is more useful with a dated trend than a remembered lowest weight. Treatment duration, prescribed changes, missed doses and interruptions in supply help describe the course of treatment.
The goal is an accurate account, not a test of willpower. A medication plan that has been difficult to follow needs that difficulty identified before its effect can be interpreted.
Include symptoms and daily function
Appetite changes, gastrointestinal symptoms and ability to maintain food and fluid intake matter. Semaglutide's label describes nausea, vomiting, diarrhea and other adverse effects, including dehydration-related kidney injury.[2]
A lower number on the scale is not the only relevant finding if treatment is also causing persistent symptoms. Conversely, stable weight after earlier loss may need a different discussion from no meaningful benefit since starting.
A switch needs a specific reason
NIDDK describes several possible responses when a weight-management plan is not working as intended, including reviewing lifestyle support, other medicines and alternative treatment. Switching is one option, not a conclusion produced by the word “plateau.”[1]
Tirzepatide has its own contraindications, adverse effects and reproductive considerations. Its dual-receptor mechanism does not eliminate those questions.[3]
Avoid an improvised transition
The prescribing provider should determine whether to continue, change or stop treatment and give product-specific instructions. The labels caution against combining these products with other GLP-1 medicines.[2][3]
The review should leave a clear reason for the next step and a date to reassess its effects.
